HC Wainwright Has Positive View of CalciMedica Q3 Earnings

CalciMedica Inc. (NASDAQ:CALC) – Equities researchers at HC Wainwright raised their Q3 2026 earnings estimates for CalciMedica in a report released on Wednesday, May 13th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.37). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q4 2026 earnings at ($0.46) EPS and FY2026 earnings at ($1.35) EPS.

Several other analysts also recently issued reports on CALC. Oppenheimer lowered their price objective on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

CalciMedica Stock Down 5.6%

Shares of NASDAQ:CALC opened at $0.62 on Tuesday. CalciMedica has a 52-week low of $0.46 and a 52-week high of $7.20. The company has a 50 day moving average of $0.64 and a two-hundred day moving average of $2.49. The company has a market capitalization of $9.80 million, a price-to-earnings ratio of -0.47 and a beta of 0.85.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On CalciMedica

Several large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its stake in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares during the last quarter. 180 Wealth Advisors LLC lifted its stake in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after purchasing an additional 34,386 shares during the last quarter. Boothbay Fund Management LLC bought a new position in CalciMedica during the fourth quarter worth $506,000. Finally, Stonehage Fleming Financial Services Holdings Ltd bought a new position in CalciMedica during the third quarter worth $165,000.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.